Session » Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2133

Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016

9:00AM-11:00AM: Abstract Number: 2128

Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality

9:00AM-11:00AM: Abstract Number: 2136

Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology

9:00AM-11:00AM: Abstract Number: 2157

Checkpoint Inhibitor-Associated Arthritis: Phenotype, Steroid Dose, Serology and Survival

9:00AM-11:00AM: Abstract Number: 2132

Complement Component 3 as Biomarker of Cardiometabolic Risk in Rheumatic Diseases: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2146

Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease

9:00AM-11:00AM: Abstract Number: 2130

Enrichment of IL-17-producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis After anti-CTLA-4 and anti-PD-1 Combination Therapy

9:00AM-11:00AM: Abstract Number: 2156

Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome

9:00AM-11:00AM: Abstract Number: 2134

Extracellular Adenosine Increases IL-6 Production by Aging Tenocytes and May Contribute to the Age-related Pattern of Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2142

Frailty in Systemic Rheumatic Diseases: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2150

Frequency of Polyautoimmunity in a Tertiary Hospital

9:00AM-11:00AM: Abstract Number: 2145

Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 2148

Muscle Involvement Revealed by 18F-PET-CT in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2144

Musculoskeletal Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy: Single Center Experience

9:00AM-11:00AM: Abstract Number: 2147

Musculoskeletal Ultrasound Enhances the Evaluation of Checkpoint Inhibitor Associated Musculoskeletal Immune Related Adverse Events

9:00AM-11:00AM: Abstract Number: 2143

Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center

9:00AM-11:00AM: Abstract Number: 2153

Ocular Scleral Pathology and Relationship with Autoimmune Diseases: Study of 101 Patients from a Single Universitary Centre

9:00AM-11:00AM: Abstract Number: 2137

Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma

9:00AM-11:00AM: Abstract Number: 2159

Pachymeningitis in Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 2151

Patient Reported Outcomes and Factors Predicting Clinical Disease Activity in Patients with Immune-Checkpoint Inhibitor Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2140

Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

9:00AM-11:00AM: Abstract Number: 2149

Principal Components Analysis as a Tool to Identify Lesional Skin Patterns in Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2158

Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)

9:00AM-11:00AM: Abstract Number: 2138

Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population

9:00AM-11:00AM: Abstract Number: 2139

Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases

9:00AM-11:00AM: Abstract Number: 2131

Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2141

Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients

9:00AM-11:00AM: Abstract Number: 2154

Role of Insulin Resistance and Inflammation on Resting Energy Expenditure in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2152

Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2155

The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation

9:00AM-11:00AM: Abstract Number: 2135

Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features

9:00AM-11:00AM: Abstract Number: 2129

Thyroperoxidase Antibodies in Patients with Positive ANA

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].